Journal of Blood Disorders & Transfusion

Division of Hematolgy, University of Khartoum, Khartoum, Sudan

Publications

• Review Article   
  Eltrombopag: A Review of Its Use in Patients with Systemic Lupus Erythematosus Associated Immune Thrombocytopenia
  Author(s): Waniot Iva and Ana Eash*
  
  Systemic Lupus Erythematosus (SLE) is an autoimmune disease that primarily affects young women of childbearing age. Thrombocytopenia is a relatively common hematologic manifestation of SLE, occurring in approximately 20-30% of SLE patients. The etiology of SLE thrombocytopenia is primarily autoimmune mediated and classified as Immune thrombocytopenia (ITP). Studies have shown that mortality is significantly higher in SLE patients with thrombocytopenia than non-thrombocytopenic patients. The mortality rate of patients in complete remission after treatment is significantly lower than that of patients in incomplete remission. Therefore, complete recovery from thrombocytopenia is important for the survival of patients with SLE. Eltrombopag is an oral Thrombopoietin Receptor (TPO-R) agonist that promotes the proliferation and differentiation of multifetal hematopoietic stem cells and megak.. View more»
  

  Abstract HTML PDF